162 related articles for article (PubMed ID: 1617509)
1. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
Goel V; Naylor CD
Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
Lorenzoni R; Fattore G; Gensini G
G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
[TBL] [Abstract][Full Text] [Related]
4. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
[TBL] [Abstract][Full Text] [Related]
5. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
Tsui W; Pierre K; Massel D
Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
[TBL] [Abstract][Full Text] [Related]
6. Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.
Massel D
Can J Cardiol; 1999 Feb; 15(2):173-9. PubMed ID: 10079776
[TBL] [Abstract][Full Text] [Related]
7. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.
Kaul P; Armstrong PW; Chang WC; Naylor CD; Granger CB; Lee KL; Peterson ED; Califf RM; Topol EJ; Mark DB
Circulation; 2004 Sep; 110(13):1754-60. PubMed ID: 15381645
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
Newby LK; Eisenstein EL; Califf RM; Thompson TD; Nelson CL; Peterson ED; Armstrong PW; Van de Werf F; White HD; Topol EJ; Mark DB
N Engl J Med; 2000 Mar; 342(11):749-55. PubMed ID: 10717009
[TBL] [Abstract][Full Text] [Related]
12. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
Lessler DS; Avins AL
Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of the cost effectiveness of treatment of acute myocardial infarct with primary angioplasty and thrombolysis ].
Golán L; Simek S; Linhart A; Cahlík T; Palecek T; Lubanda JC; Korínek J; Beran S; Aschermann M
Vnitr Lek; 2003 Feb; 49(2):97-102. PubMed ID: 12728575
[TBL] [Abstract][Full Text] [Related]
14. Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI; White HD; Modan M; Diaz R; Hampton JR; Heikkila J; Kristinsson A; Moulopoulos S; Paolasso EA; Van der Werf T
Arch Intern Med; 1994 Oct; 154(19):2237-42. PubMed ID: 7944845
[TBL] [Abstract][Full Text] [Related]
15. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic therapy in acute coronary thrombosis.
Ramalanjaona GR; Mathew JC
Indiana Med; 1990 Jun; 83(6):410-2. PubMed ID: 2112180
[TBL] [Abstract][Full Text] [Related]
17. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
[TBL] [Abstract][Full Text] [Related]
18. Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
Müllner M; Paulis M; Nikfardjam M; Domanovits H; Huber K
Wien Klin Wochenschr; 1999 Jan; 111(1):37-41. PubMed ID: 10067269
[TBL] [Abstract][Full Text] [Related]
19. Streptokinase and tissue plasminogen activator in acute myocardial infarction.
Brewer CC; Markis JE
Heart Lung; 1986 Nov; 15(6):552-8. PubMed ID: 3095269
[TBL] [Abstract][Full Text] [Related]
20. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Kent DM; Hayward RA; Griffith JL; Vijan S; Beshansky JR; Califf RM; Selker HP
Am J Med; 2002 Aug; 113(2):104-11. PubMed ID: 12133748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
